Visualizing the distribution of durvalumab targeting PD-L1 using quantitative fluorescence imaging in patients with esophageal cancer.
van der Waaij AM, van Ginkel YJ, Volkmer P, Kats-Ugurlu G, Huizinga HK, Hone Lopez S, de Haan JJ, Bijlsma R, van der Waaij LA, Muijs CT, Niezink AGH, van Etten B, Westerhof J, di Pietro M, Robinson DJ, Lub-de Hooge MN, Nagengast WB
The online reader was unable to display this document directly. This may occur if the repository host is temporarily unreachable, or if security restrictions (CORS) prevent embedded viewing.